Replies to post #156 on Alnylam Pharmaceuticals Inc (ALNY)

[Wildbilly]

Alnylam Initiates EXPLORE, a Prospective Observational Study of Patients with Hepatic Porphyrias

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and collaborators from the American Porphyria Consortium and The European Porphyria Network have initiated the EXPLORE trial, a prospective observational study of patients with hepatic porphyrias, including Acute Intermittent Porphyria (AIP), Variegate Porphyria, and Hereditary Coproporphyria, suffering from recurrent attacks. With this study, Alnylam and clinical investigators aim to learn more about the clinical course, management, and disease burden of patients with hepatic porphyrias that suffer from recurrent attacks. Alnylam is currently advancing ALN-AS1, a subcutaneously administered investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS-1) for the treatment of hepatic porphyrias, and expects to file an IND or IND equivalent in late 2014 or early 2015.

Read more: .http://www.businesswire.com/portal/site/biospace/index.jsp?ndmViewId=news_view&newsId=20141001005203&newsLang=en



.